Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) EPS (Basic) (2016 - 2026)

Pharma-Bio Serv filings provide 17 years of EPS (Basic) readings, the most recent being $0.0 for Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 285.84% to $0.0 in Q1 2026 year-over-year; TTM through Jan 2026 was -$0.0, a 82.78% increase, with the full-year FY2025 number at -$0.0, up 87.07% from a year prior.
  • EPS (Basic) hit $0.0 in Q1 2026 for Pharma-Bio Serv, up from -$0.0 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.02 in Q3 2023 to a low of -$0.01 in Q3 2024.
  • Median EPS (Basic) over the past 5 years was $0.0 (2026), compared with a mean of $0.0.
  • Biggest five-year swings in EPS (Basic): plummeted 163.44% in 2024 and later soared 285.84% in 2026.
  • Pharma-Bio Serv's EPS (Basic) stood at $0.01 in 2022, then tumbled by 127.23% to -$0.0 in 2023, then skyrocketed by 134.18% to $0.0 in 2024, then plummeted by 100.63% to -$0.0 in 2025, then skyrocketed by 32374.05% to $0.0 in 2026.
  • The last three reported values for EPS (Basic) were $0.0 (Q1 2026), -$0.0 (Q4 2025), and -$0.01 (Q3 2025) per Business Quant data.